Urovant Presents Interim Results of URO-902 in P-IIa Study for the Treatment of Overactive Bladder at AUA 2022
Shots:
- The P-IIa trial evaluates URO-902 (24/48mg) vs PBO in 80 female patients with OAB who have not been adequately managed with oral or transdermal pharmacologic therapy
- The results showed that patients treated with URO-902 at both doses showed clinically relevant improvement in mean daily urination, urgency episodes, UUI episodes, OAB questionnaire symptom bother score & global impression of change responders @12wk., TEAEs (45.5%/46.2% vs 50.0%), 1 patient in 48mg dose had asymptomatic elevated post-void residual urine volume @2wk.
- In prespecified 12wk. analysis, patients showed a clinically relevant improvement in efficacy & was well tolerated in women with OAB & UUI who have failed oral therapies
Ref: Urovant | Image: Urovant Sciences
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
